Amicus Therapeutics (FOLD) Competitors $5.95 +0.11 (+1.88%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$5.78 -0.17 (-2.77%) As of 07/2/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FOLD vs. RGEN, HALO, MDGL, IONS, ALKS, LGND, BCRX, CLDX, INVA, and DVAXShould you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Repligen (RGEN), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Innoviva (INVA), and Dynavax Technologies (DVAX). These companies are all part of the "biotechnology" industry. Amicus Therapeutics vs. Its Competitors Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Ionis Pharmaceuticals Alkermes Ligand Pharmaceuticals BioCryst Pharmaceuticals Celldex Therapeutics Innoviva Dynavax Technologies Repligen (NASDAQ:RGEN) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk. Which has more risk and volatility, RGEN or FOLD? Repligen has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Which has better valuation & earnings, RGEN or FOLD? Repligen has higher revenue and earnings than Amicus Therapeutics. Repligen is trading at a lower price-to-earnings ratio than Amicus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepligen$634.44M11.24-$25.51M-$0.45-282.13Amicus Therapeutics$528.29M3.47-$56.11M-$0.09-66.11 Does the media prefer RGEN or FOLD? In the previous week, Repligen had 6 more articles in the media than Amicus Therapeutics. MarketBeat recorded 7 mentions for Repligen and 1 mentions for Amicus Therapeutics. Repligen's average media sentiment score of 1.09 beat Amicus Therapeutics' score of 0.43 indicating that Repligen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amicus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer RGEN or FOLD? Repligen currently has a consensus target price of $172.83, suggesting a potential upside of 36.13%. Amicus Therapeutics has a consensus target price of $16.22, suggesting a potential upside of 172.64%. Given Amicus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Amicus Therapeutics is more favorable than Repligen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repligen 0 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.69Amicus Therapeutics 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.70 Is RGEN or FOLD more profitable? Repligen has a net margin of -3.93% compared to Amicus Therapeutics' net margin of -5.41%. Amicus Therapeutics' return on equity of 4.67% beat Repligen's return on equity.Company Net Margins Return on Equity Return on Assets Repligen-3.93% 4.53% 3.17% Amicus Therapeutics -5.41%4.67%1.05% Do institutionals and insiders hold more shares of RGEN or FOLD? 97.6% of Repligen shares are held by institutional investors. 1.2% of Repligen shares are held by company insiders. Comparatively, 2.2% of Amicus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryRepligen beats Amicus Therapeutics on 10 of the 16 factors compared between the two stocks. Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FOLD vs. The Competition Export to ExcelMetricAmicus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.80B$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-66.1021.3126.1919.90Price / Sales3.47278.47414.67113.66Price / CashN/A41.4736.1356.90Price / Book9.157.518.055.38Net Income-$56.11M-$55.05M$3.15B$248.50M7 Day Performance4.57%2.07%1.48%2.06%1 Month Performance-4.95%4.84%3.66%4.86%1 Year Performance-39.35%5.37%34.93%20.24% Amicus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FOLDAmicus Therapeutics4.0426 of 5 stars$5.95+1.9%$16.22+172.6%-39.6%$1.80B$528.29M-66.10480RGENRepligen4.8085 of 5 stars$120.11+1.1%$173.25+44.2%+5.7%$6.75B$634.44M-266.911,778Positive NewsHALOHalozyme Therapeutics4.8145 of 5 stars$52.800.0%$61.90+17.2%+5.0%$6.51B$1.02B14.04390Analyst RevisionMDGLMadrigal Pharmaceuticals3.9841 of 5 stars$282.99-1.0%$420.63+48.6%+10.5%$6.28B$180.13M-15.6890IONSIonis Pharmaceuticals4.606 of 5 stars$37.67+0.7%$57.59+52.9%-3.4%$6.00B$705M-12.601,069News CoverageAnalyst UpgradeALKSAlkermes4.9168 of 5 stars$29.26+0.6%$40.00+36.7%+19.9%$4.82B$1.56B14.001,800News CoveragePositive NewsAnalyst RevisionLGNDLigand Pharmaceuticals4.7284 of 5 stars$114.97+0.8%$146.14+27.1%+34.0%$2.22B$167.13M-16.1580News CoverageBCRXBioCryst Pharmaceuticals4.4713 of 5 stars$9.91-1.9%$16.56+67.1%+37.7%$2.07B$450.71M-38.12530Trending NewsAnalyst ForecastAnalyst RevisionCLDXCelldex Therapeutics3.1669 of 5 stars$20.39-0.5%$50.11+145.8%-40.3%$1.35B$7.02M-7.55150Positive NewsINVAInnoviva4.1706 of 5 stars$20.82-0.9%$55.00+164.2%+17.6%$1.31B$358.71M-20.61100Positive NewsDVAXDynavax Technologies4.4291 of 5 stars$9.77-2.2%$24.00+145.6%-8.3%$1.17B$277.25M-18.79350 Related Companies and Tools Related Companies RGEN Alternatives HALO Alternatives MDGL Alternatives IONS Alternatives ALKS Alternatives LGND Alternatives BCRX Alternatives CLDX Alternatives INVA Alternatives DVAX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FOLD) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredConsumer apocalypse imminent (7 ominous red flags)The #1 Gold play right now (not a miner, ETF, or bullion) Gold is up 237% since 2008... but one gold invest...Stansberry Research | SponsoredMake 22x more from this summer’s Bitcoin boomBitcoin is on fire again. Wall Street’s piling in. ETFs are smashing volume records. And regular investors ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
